Skip to search formSkip to main contentSkip to account menu

liarozole

An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (5)

Androgen AntagonistsAntineoplastic Agents, HormonalDermatologic AgentsEnzyme Inhibitors
Liarozole HydrochlorideNCIt Antineoplastic Agent Terminologyliarozole fumarate

Narrower (3)

LiazalR 085246R 75251

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy
Uterine leiomyomas are the most common tumors of the female genital tract, affecting 50% to 70% of females by the age of 50… 
Review
2006
Review
2006
Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Highly Cited
2001
Highly Cited
2001
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double‐blind, placebo‐controlled study
Background Palmoplantar pustular psoriasis (PPP) is a chronic, relapsing condition often recalcitrant to therapy. Synthetic… 
Highly Cited
1999
Highly Cited
1999
Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity.
1α,25-Dihydroxyvitamin D3[ 1,25-(OH)2D3] inhibits the proliferation of many cancer cells in culture, but not the aggressive human… 
Review
1998
Review
1998
The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
Although significant advances have been made in the treatment of some malignancies, the prognosis of patients with metastatic… 
1998
1998
The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin
The imidazole derivative liarozole is a potent inhibitor of cytochrome P450‐dependent 4‐hydroxyla‐tion of endogenous all‐trans… 
1995
1995
Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells.
Liarozole has been reported to inhibit P450 enzymes responsible for the catabolism of retinoic acid. This suggests that it may… 
Review
1993
Review
1993
Ketoconazole and liarozole in the treatment of advanced prostatic cancer
Background. Ketoconazole, an imidazole derivative, is an orally active antifungal agent. In high doses (400 mg three times a day… 
Highly Cited
1992
Highly Cited
1992
Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid… 
Highly Cited
1992
Highly Cited
1992
Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.
Liarozole is a new imidazole derivative with antitumoral properties. Effects of the compound alone and in combination with all… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License